Bottom line
IHE vs IXJ: the short answer
IHE (iShares U.S. Pharmaceuticals ETF) and IXJ (iShares Global Healthcare ETF) are quite different portfolios: only about 35% of their top holdings (by weight) are shared.
But IXJ is far broader, holding 124 positions to 59 for IHE, so beyond the top names it adds exposure IHE doesn't have.
IHE is cheaper at 0.37% vs 0.38% — a difference of $1.00 a year per $10,000 invested.
Over five years, IHE returned +9.1% a year vs +6.4% for IXJ.
Updated Nov 19, 2026
IHE vs IXJ side by side
| IHE | IXJ | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.37% | 0.38% |
| Annual cost per $10k | $37 | $38 |
| 10-yr cost on $10k (prospectus) | $468 | $480 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +31.7% | +14.9% |
| 5-yr return (annualized) | +9.1% | +6.4% |
| 10-yr return (annualized) | +6.2% | +8.2% |
| Best quarter | +17.6% | +13.6% |
| Worst quarter | −16.0% | −11.8% |
| Net assets (fund) | $1.1B | $3.8B |
| Number of holdings | 59 | 124 |
| Portfolio turnover | 29% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IHE | IXJ | Difference |
|---|---|---|---|
| 2025 | +31.7% | +14.9% | +16.9% |
| 2024 | +8.1% | +0.6% | +7.5% |
| 2023 | +1.0% | +3.5% | −2.5% |
| 2022 | −4.8% | −4.7% | −0.1% |
| 2021 | +12.8% | +19.5% | −6.7% |
| 2020 | +13.8% | +12.5% | +1.3% |
| 2019 | +15.5% | +23.4% | −7.9% |
| 2018 | −7.7% | +2.9% | −10.5% |
| 2017 | +10.7% | +20.3% | −9.7% |
| 2016 | −11.7% | −6.2% | −5.5% |
Source: Fund prospectus bar charts
Holdings overlap
5 of IHE's top 25 holdings also appear in IXJ's top 25.
| Holding | IHE | IXJ |
|---|---|---|
| Johnson & Johnson | 22.44% | 7.04% |
| Eli Lilly And Company | 22.25% | 10.93% |
| Merck & Co., Inc. | 4.55% | 4.12% |
| Bristol-myers Squibb Company | 4.37% | 1.53% |
| Pfizer Inc. | 3.96% | 1.78% |
Source: SEC Form N-PORT
IHE top 10
- Johnson & Johnson — 22.44%
- Eli Lilly And Company — 22.25%
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 6.24%
- Merck & Co., Inc. — 4.55%
- Bristol-myers Squibb Company — 4.37%
- Royalty Pharma Plc — 4.34%
- Viatris Inc. — 4.22%
- Pfizer Inc. — 3.96%
- Zoetis Inc. — 3.73%
- Jazz Pharmaceuticals Public Limited Company — 3.45%
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
FAQ
What is the difference between IHE and IXJ?
Which is cheaper, IHE or IXJ?
Should I own both IHE and IXJ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.